Startups
Wondfo, a leader in China's POCT industry, has been committed to improving patient care, safeguarding lives, and driving efficiency in the healthcare system with effective POC products and solutions since 1992.
Today, Wondfo has more than 3000 employees and a wide range of rapid diagnostic reagents and instruments for the quantitative determination of biomarkers for early identification of cardiovascular disease, diabetes, tumor, inflammation, infectious disease, as well as drug abuse tests, pregnancy tests, etc.
Wondfo has a comprehensive quality management system and strictly complies with industry standards and regulations. Products are recognized by NMPA, CE, FDA, MDALL, WHO PQ, etc.
Here, everything we do is to safeguard the health and improve the lives of people worldwide. With this in mind, we’ll continue to innovate and shape the future of POCT and healthcare.
Today, Wondfo has more than 3000 employees and a wide range of rapid diagnostic reagents and instruments for the quantitative determination of biomarkers for early identification of cardiovascular disease, diabetes, tumor, inflammation, infectious disease, as well as drug abuse tests, pregnancy tests, etc.
Wondfo has a comprehensive quality management system and strictly complies with industry standards and regulations. Products are recognized by NMPA, CE, FDA, MDALL, WHO PQ, etc.
Here, everything we do is to safeguard the health and improve the lives of people worldwide. With this in mind, we’ll continue to innovate and shape the future of POCT and healthcare.
Overview
Location
China, Guangdong, Guangzhou
Employees
1001-5000
Phone
+86 20 3229 6083
Founded date
1992
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 9, 2026 | Global In Vitro Diagnostic (IVD) Products Market Share, Growth Drivers, Trends, Overall Sales and Demand Forecast To 2032 | The Global In Vitro Diagnostic (IVD) Products Market is witnessing remarkable growth as healthcare systems worldwide prioritize early disease detection, personalized treatment, and preventive care. In vitro diagnostic products have become a... |
| Sep 7, 2021 | Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 80 million worth of its shares. | Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces a share repurchase program. Under the program, the company will repurchase up to CNY 80 million worth of its shares. The shares will be repurchased at a price not more than CNY 77.92 ... |
| Jan 23, 2017 | Atlas Genetics Raises $35M in Series D Funding | Atlas Genetics Ltd., a Bath, England, UK-based ultra-rapid Point-Of-Care (POC) molecular diagnostics company, closed $35m in Series D financing. Backers included existing investors Novartis Venture Funds, Consort Medical plc, Johnson & ... |
Reviews 0
FAQ about Wondfo
When was Wondfo founded?
Wondfo was founded in 1992.
What has the press written about Wondfo?
Parsers VC has collected 4 articles mentioning Wondfo, among them “Global In Vitro Diagnostic (IVD) Products Market Share, Growth Drivers, Trends, Overall Sales and Demand Forecast To 2032” (Jul 9, 2026) and “Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 80 million worth of its shares.” (Sep 7, 2021).
Is Wondfo still active?
Yes, Wondfo is active; its latest activity on Parsers VC dates from Sep 3, 2026.